Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Interest & Investment Income (2016 - 2025)

Rocket Pharmaceuticals' Interest & Investment Income history spans 10 years, with the latest figure at $690000.0 for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 57.33% year-over-year to $690000.0; the TTM value through Dec 2025 reached $3.2 million, down 61.07%, while the annual FY2025 figure was $3.2 million, 61.07% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $690000.0 at Rocket Pharmaceuticals, down from $709000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.0 million in Q1 2024 and bottomed at $483000.0 in Q2 2025.
  • The 5-year median for Interest & Investment Income is $880500.0 (2021), against an average of $1.2 million.
  • The largest annual shift saw Interest & Investment Income surged 258.65% in 2021 before it plummeted 78.95% in 2025.
  • A 5-year view of Interest & Investment Income shows it stood at $850000.0 in 2021, then surged by 46.47% to $1.2 million in 2022, then crashed by 34.62% to $814000.0 in 2023, then skyrocketed by 98.65% to $1.6 million in 2024, then plummeted by 57.33% to $690000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Interest & Investment Income are $690000.0 (Q4 2025), $709000.0 (Q3 2025), and $483000.0 (Q2 2025).